UNH
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated historical holders
total: 37
Lountzis Asset Management UnitedHealth Group Incorporated transactions over time
- Total transactions:
- 21
- New positions:
- 1
- Added:
- 3
- Reduced:
- 17
- Held since:
- 2020 Q2
- Held for:
- 25 quarters
- Latest activity:
- 2026 Q2
Paul Lountzis has been an institutional investor in UnitedHealth Group Incorporated (UNH) since 2020 Q2. According to 2026 Q2 report, Paul Lountzis holds 10,122 shares with a market value of roughly $4.21M representing 1.33% of their equity portfolio. The fund/company first acquired UNH in 2020 Q2, initially purchasing 12,581 shares. Since the initial investment, Lountzis Asset Management has made 20 more transactions in this position.
Does Paul Lountzis still hold UNH?
Yes, Paul Lountzis continues to hold UnitedHealth Group Incorporated (UNH). According to their 2026 Q2 report, they maintain a position of 10,122 shares valued at approximately $4.21M, representing 1.33% of their equity portfolio.
When did Paul Lountzis first invest in UNH?
Paul Lountzis first invested in UnitedHealth Group Incorporated (UNH) in 2020 Q2 at the reported quarter-end price of $294.97 per share, acquiring 12,581 shares in their initial purchase.
What is Paul Lountzis's average cost basis for UNH?
Based on historical transaction data, Paul Lountzis's estimated cost basis for UnitedHealth Group Incorporated (UNH) is approximately $306.12 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $306.12
- Weighted AVG sell price:
- $462.60
UNH transactions history by Lountzis Asset Management
21 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
1.33%
|
10,122
|
$415.63
|
$4,207,007
|
-5.24% (-560)
|
-0.09%
|
|
2026 Q1
|
1.06%
|
10,682
|
$270.59
|
$2,890,442
|
-0.11% (-12)
|
-0%
|
|
2025 Q4
|
1.25%
|
10,694
|
$330.11
|
$3,530,196
|
-1.43% (-155)
|
-0.02%
|
|
2025 Q1
|
1.72%
|
10,849
|
$420.00
|
$4,556,580
|
-1.65% (-182)
|
-0.03%
|
|
2024 Q4
|
2.36%
|
11,031
|
$505.86
|
$5,580,142
|
-3.62% (-414)
|
-0.09%
|
|
2024 Q3
|
2.78%
|
11,445
|
$584.68
|
$6,691,662
|
+0.04% (+5)
|
+0%
|
|
2024 Q2
|
2.72%
|
11,440
|
$509.26
|
$5,825,934
|
-0.48% (-55)
|
-0.01%
|
|
2023 Q4
|
3.30%
|
11,495
|
$526.47
|
$6,051,773
|
-0.68% (-79)
|
-0.02%
|
|
2023 Q2
|
3.26%
|
11,574
|
$510.89
|
$5,913,000
|
-7.23% (-902)
|
-0.27%
|
|
2023 Q1
|
3.49%
|
12,476
|
$472.59
|
$5,896,000
|
+7.03% (+819)
|
+0.23%
|
|
2022 Q4
|
3.33%
|
$475.17
|
+0.13% (+15)
|
|||
|
2022 Q3
|
3.99%
|
$504.98
|
-2.33% (-278)
|
|||
|
2022 Q2
|
4.10%
|
$513.59
|
-1.46% (-177)
|
|||
|
2022 Q1
|
3.42%
|
$509.97
|
-0.09% (-11)
|
|||
|
2021 Q4
|
3.47%
|
$502.14
|
-0.31% (-38)
|
|||
|
2021 Q3
|
2.96%
|
$390.74
|
-0.17% (-21)
|
|||
|
2021 Q2
|
2.97%
|
$400.35
|
-2.17% (-270)
|
|||
|
2021 Q1
|
3.08%
|
$372.04
|
-0.51% (-64)
|
|||
|
2020 Q4
|
3.22%
|
$350.69
|
-0.24% (-30)
|
|||
|
2020 Q3
|
3.36%
|
$311.79
|
-0.40% (-50)
|
|||
|
2020 Q2
|
3.52%
|
$294.97
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.